Oligofructose fermentation modulates the release of gut hormones in the blood which act as signalling agents to the brain influencing appetite and ultimately food intake.
The company claims that a study in rats fed either a diet supplemented with BeneoTMP95 or BeneoTMSynergy1 (10%) or a standard diet (control) for 3 weeks showed significantly lower energy intake in the three groups of rats fed the test diets compared to the control group (P<0.05). This led to a significant decrease in body fat mass after 3 weeks for both groups (30% decrease) vs. controls (P<0.01).
Parallel with these observations, the plasma level of the satiety inducing gut peptide GLP-1 was significantly higher in the rats fed oligofructose than in the control animals (P<0.05). Conversely,, the plasma level of ghrelin (hormone that stimulates food intake) remained significantly lower in the BeneoTMP95 and BeneoTMSynergy1 animals than in the control rats (P<0.05). Normally plasma ghrelin concentration increases during a period of food deprivation, signalling a feeling of hunger to the brain. These levels then fall rapidly after a meal is ingested.
A subsequent study was undertaken in an animal model for obesity where rats were fed a high fat diet with and without BeneoTMP95 (10%) for 2 weeks. Energy intake was significantly lower in the high-fat BeneoTMP95-supplemented group than in the high-fat control group (P<0.05). Weight gain during the high-fat diet was significantly lower in the rats receiving the diet enriched with BeneoTMP95 than in those receiving the high-fat diet without BeneoTMP95 (P<0.05). The total weight of the adipose tissue also was lower (by a factor of 2) in the BeneoTMP95 fed animals than in the control animals (P<0.05).
People wary of vaccinated chicken meat